Machida H, Nishitani M
Biology Laboratory, R & D Division, Yamasa Shoyu Co., Ltd., Chiba.
Microbiol Immunol. 1990;34(4):407-11. doi: 10.1111/j.1348-0421.1990.tb01023.x.
Susceptibilities to brovavir [1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)-uracil] and acyclovir of clinical isolates of varicella-zoster virus obtained from 58 patients with herpes zoster, included in a clinical trial of oral brovavir, were tested by a plaque reduction method. All 101 isolates were significantly susceptible to brovavir; 50% effective dose of brovavir for these isolates ranged between 0.6-4.0 ng/ml (average: 1.29 ng/ml). Brovavir was about 3,000 times more potent than acyclovir against these isolates. No marked change in the susceptibility of isolates from these patients during treatment with brovavir was observed.
在一项口服溴夫定的临床试验中，对从58例带状疱疹患者身上分离出的水痘-带状疱疹病毒临床分离株进行了溴夫定[1-β-D-阿拉伯呋喃糖基-E-5-(2-溴乙烯基)-尿嘧啶]和阿昔洛韦敏感性测试，采用蚀斑减少法。所有101株分离株对溴夫定均有显著敏感性；这些分离株的溴夫定半数有效剂量在0.6-4.0 ng/ml之间（平均：1.29 ng/ml）。溴夫定对这些分离株的效力比阿昔洛韦高约3000倍。在使用溴夫定治疗期间，未观察到这些患者的分离株敏感性有明显变化。
